Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and TSEBT in Mycosis Fungoides and Sézary Syndrome
NCT03617224Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jul 2018
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by UT Southwestern Medical Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Planned start Jul 2018; status: withdrawn.
02
Drugs
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT03617224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617224.